Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 1/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.40 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.40 |
| ▸ | IL2 | P60568 | 10/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 4/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838584 | 0.87 | SCN9A (0.34) | STIM1ORAI1ORAI2IL2ABL1 | |
| SCHEMBL13838327 | 0.79 | IL2 (0.43) | IL2ABL1 | |
| SCHEMBL13838556 | 0.78 | IL2 (0.44) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL13838376 | 0.77 | STIM1 (0.41) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL13838380 | 0.76 | GRM5 (0.45) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL13838379 | 0.75 | GRM5 (0.45) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL13838382 | 0.75 | GRM5 (0.45) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL13838336 | 0.75 | IL2 (0.43) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL15803791 | 0.75 | IL2 (0.44) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL13838577 | 0.75 | IL2 (0.35) | IL2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012151355-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-08 | — | — | WO | disclosed |